NZ598234B - Treatment and/or prevention of inflammation and cutaneous photodamage and photoprotection of the skin with a water-soluble extract from plant of solanum genus - Google Patents
Treatment and/or prevention of inflammation and cutaneous photodamage and photoprotection of the skin with a water-soluble extract from plant of solanum genus Download PDFInfo
- Publication number
- NZ598234B NZ598234B NZ598234A NZ59823412A NZ598234B NZ 598234 B NZ598234 B NZ 598234B NZ 598234 A NZ598234 A NZ 598234A NZ 59823412 A NZ59823412 A NZ 59823412A NZ 598234 B NZ598234 B NZ 598234B
- Authority
- NZ
- New Zealand
- Prior art keywords
- water
- soluble extract
- solanum
- medicament
- administered
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 127
- 241000207763 Solanum Species 0.000 title claims abstract description 43
- 235000002634 Solanum Nutrition 0.000 title claims abstract description 43
- 241000196324 Embryophyta Species 0.000 title claims abstract description 37
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 32
- 230000004054 inflammatory process Effects 0.000 title claims abstract description 32
- 210000003491 Skin Anatomy 0.000 title claims description 57
- 230000003711 photoprotective Effects 0.000 title description 5
- 230000002265 prevention Effects 0.000 title description 4
- MBWUSSKCCUMJHO-ZGXDEBHDSA-N Solamargine Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@@H]1CC2=CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(NC[C@H](C)CC1)O5)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O MBWUSSKCCUMJHO-ZGXDEBHDSA-N 0.000 claims abstract description 28
- MBWUSSKCCUMJHO-DVDUUUGDSA-N Solamargine Natural products O([C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](CO)O[C@@H]1O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]5[C@@H](C)[C@@]6(O[C@H]5C4)NC[C@H](C)CC6)CC3)CC=2)CC1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](C)O1 MBWUSSKCCUMJHO-DVDUUUGDSA-N 0.000 claims abstract description 28
- QCTMYNGDIBTNSK-QCNFCIKQSA-N Solasonine Natural products O([C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](C)O2)[C@@H](O[C@@H]2CC=3[C@@](C)([C@@H]4[C@H]([C@H]5[C@@](C)([C@H]6[C@@H](C)[C@@]7(O[C@H]6C5)NC[C@H](C)CC7)CC4)CC=3)CC2)O[C@@H](CO)[C@@H]1O)[C@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 QCTMYNGDIBTNSK-QCNFCIKQSA-N 0.000 claims abstract description 28
- QCTMYNGDIBTNSK-XEAAVONHSA-N α-Solamarine Chemical compound O([C@H]1[C@@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@@H]1CC2=CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(NC[C@H](C)CC1)O5)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QCTMYNGDIBTNSK-XEAAVONHSA-N 0.000 claims abstract description 28
- 239000000203 mixture Substances 0.000 claims abstract description 24
- 239000003814 drug Substances 0.000 claims abstract description 22
- 238000004519 manufacturing process Methods 0.000 claims abstract description 15
- 239000002537 cosmetic Substances 0.000 claims abstract description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 230000000699 topical Effects 0.000 claims description 11
- 210000004177 Elastic Tissue Anatomy 0.000 claims description 9
- 230000036285 pathological change Effects 0.000 claims description 8
- 238000001764 infiltration Methods 0.000 claims description 7
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 5
- 206010040799 Skin atrophy Diseases 0.000 claims description 4
- 239000002738 chelating agent Substances 0.000 claims description 4
- 239000003086 colorant Substances 0.000 claims description 4
- 239000000835 fiber Substances 0.000 claims description 4
- 239000003349 gelling agent Substances 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- 102000008186 Collagen Human genes 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 3
- 210000004969 Inflammatory Cells Anatomy 0.000 claims description 3
- 230000000240 adjuvant Effects 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 230000032683 aging Effects 0.000 claims description 3
- 230000000111 anti-oxidant Effects 0.000 claims description 3
- 229960005188 collagen Drugs 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- 239000003205 fragrance Substances 0.000 claims description 3
- 230000002028 premature Effects 0.000 claims description 3
- 230000002335 preservative Effects 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 239000002562 thickening agent Substances 0.000 claims description 3
- 230000037373 wrinkle formation Effects 0.000 claims description 3
- 206010000496 Acne Diseases 0.000 claims description 2
- 206010011732 Cyst Diseases 0.000 claims description 2
- 239000002250 absorbent Substances 0.000 claims description 2
- 230000002745 absorbent Effects 0.000 claims description 2
- 230000003213 activating Effects 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 230000002792 vascular Effects 0.000 claims description 2
- 235000000208 Solanum incanum Nutrition 0.000 description 91
- 240000006096 Solanum incanum Species 0.000 description 91
- 230000001575 pathological Effects 0.000 description 71
- 239000000499 gel Substances 0.000 description 63
- 210000001519 tissues Anatomy 0.000 description 39
- 239000000243 solution Substances 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- 210000004027 cells Anatomy 0.000 description 20
- 102000003945 NF-kappa B Human genes 0.000 description 18
- 108010057466 NF-kappa B Proteins 0.000 description 18
- SHGAZHPCJJPHSC-YCNIQYBTSA-N Retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 17
- 239000008194 pharmaceutical composition Substances 0.000 description 17
- 230000036572 transepidermal water loss Effects 0.000 description 17
- 101710040930 PTGS2 Proteins 0.000 description 16
- 102100015381 PTGS2 Human genes 0.000 description 16
- 230000014509 gene expression Effects 0.000 description 16
- 206010028980 Neoplasm Diseases 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 13
- 108090001123 antibodies Proteins 0.000 description 13
- 102000004965 antibodies Human genes 0.000 description 13
- 239000002158 endotoxin Substances 0.000 description 13
- 239000000463 material Substances 0.000 description 13
- 210000000138 Mast Cells Anatomy 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 12
- 238000001262 western blot Methods 0.000 description 12
- 102100002496 NOS2 Human genes 0.000 description 11
- 101700049309 NOS2 Proteins 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- 230000028709 inflammatory response Effects 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 238000007429 general method Methods 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000003642 reactive oxygen metabolite Substances 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 239000006071 cream Substances 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 235000001254 Solanum anguivi Nutrition 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 230000003110 anti-inflammatory Effects 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 230000037394 skin elasticity Effects 0.000 description 6
- -1 troche Substances 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 210000002540 Macrophages Anatomy 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000005755 formation reaction Methods 0.000 description 5
- 231100000915 pathological change Toxicity 0.000 description 5
- 238000004450 types of analysis Methods 0.000 description 5
- 206010029098 Neoplasm skin Diseases 0.000 description 4
- 108009000578 Oxidative Stress Proteins 0.000 description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M Sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
- 241000047306 Solanum anguivi Species 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000003247 decreasing Effects 0.000 description 4
- 238000003364 immunohistochemistry Methods 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 230000036542 oxidative stress Effects 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- GEDVVYWLPUPJJZ-UHFFFAOYSA-N (7-amino-8-methylphenothiazin-3-ylidene)-dimethylazanium;chloride Chemical compound [Cl-].N1=C2C=CC(=[N+](C)C)C=C2SC2=C1C=C(C)C(N)=C2 GEDVVYWLPUPJJZ-UHFFFAOYSA-N 0.000 description 3
- 102100011550 ACTB Human genes 0.000 description 3
- 101700033661 ACTB Proteins 0.000 description 3
- 101710032514 ACTI Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000283074 Equus asinus Species 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- 101710037135 GAPC2 Proteins 0.000 description 3
- 101710037116 GAPC3 Proteins 0.000 description 3
- 101710025049 GAPDG Proteins 0.000 description 3
- 101710008404 GAPDH Proteins 0.000 description 3
- 102100006425 GAPDH Human genes 0.000 description 3
- 101710010461 Gapdh1 Proteins 0.000 description 3
- 101710025050 MK0970 Proteins 0.000 description 3
- 241000283898 Ovis Species 0.000 description 3
- 235000017073 Solanum coagulans Nutrition 0.000 description 3
- 241000895277 Solanum coagulans Species 0.000 description 3
- 235000000212 Solanum linnaeanum Nutrition 0.000 description 3
- 235000002594 Solanum nigrum Nutrition 0.000 description 3
- 240000008759 Solanum pseudocapsicum Species 0.000 description 3
- 235000000340 Solanum pseudocapsicum Nutrition 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000003078 antioxidant Effects 0.000 description 3
- 101710025091 cbbGC Proteins 0.000 description 3
- 230000001684 chronic Effects 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 101710025070 gapdh-2 Proteins 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000000977 initiatory Effects 0.000 description 3
- 239000002609 media Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000003287 optical Effects 0.000 description 3
- 230000004792 oxidative damage Effects 0.000 description 3
- 230000001717 pathogenic Effects 0.000 description 3
- 244000052769 pathogens Species 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 235000017807 phytochemicals Nutrition 0.000 description 3
- 229930000223 plant secondary metabolites Natural products 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- 229950003937 tolonium Drugs 0.000 description 3
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 2
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 2
- 206010068388 Actinic elastosis Diseases 0.000 description 2
- KZNIFHPLKGYRTM-UHFFFAOYSA-N Apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 2
- ZIUSSTSXXLLKKK-HWUZOJPISA-N Curcumin Natural products C1=C(O)C(OC)=CC(\C=C\C(\O)=C/C(=O)/C=C/C=2C=C(OC)C(O)=CC=2)=C1 ZIUSSTSXXLLKKK-HWUZOJPISA-N 0.000 description 2
- 229960002743 Glutamine Drugs 0.000 description 2
- WZUVPPKBWHMQCE-VYIIXAMBSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@@]2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-VYIIXAMBSA-N 0.000 description 2
- 206010022114 Injury Diseases 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- OAIJSZIZWZSQBC-LWRKPGOESA-N Lycopene Natural products CC(C)=CCC\C(C)=C/C=C/C(/C)=C\C=C\C(\C)=C/C=C/C=C(/C)\C=C\C=C(\C)/C=C/C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-LWRKPGOESA-N 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108009000330 Matrix Metalloproteinases Proteins 0.000 description 2
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Resveratrol Natural products C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 2
- 210000004927 Skin cells Anatomy 0.000 description 2
- 229940054269 Sodium Pyruvate Drugs 0.000 description 2
- 235000000333 Solanum abutiloides Nutrition 0.000 description 2
- 241000193251 Solanum abutiloides Species 0.000 description 2
- 235000001238 Solanum aculeastrum Nutrition 0.000 description 2
- 241000047359 Solanum aculeastrum Species 0.000 description 2
- 235000004790 Solanum aculeatissimum Nutrition 0.000 description 2
- 240000002196 Solanum aculeatissimum Species 0.000 description 2
- 235000005166 Solanum capsicastrum Nutrition 0.000 description 2
- 244000070669 Solanum ferox Species 0.000 description 2
- 235000018253 Solanum ferox Nutrition 0.000 description 2
- 235000000204 Solanum lycocarpum Nutrition 0.000 description 2
- 241000047047 Solanum lycocarpum Species 0.000 description 2
- 235000013146 Solanum mammosum Nutrition 0.000 description 2
- 240000007710 Solanum mammosum Species 0.000 description 2
- 235000002597 Solanum melongena Nutrition 0.000 description 2
- 240000002686 Solanum melongena Species 0.000 description 2
- 240000006258 Solanum nigrum Species 0.000 description 2
- 235000014503 Solanum robustum Nutrition 0.000 description 2
- 241000689107 Solanum robustum Species 0.000 description 2
- 235000002878 Solanum suaveolens Nutrition 0.000 description 2
- 241001312092 Solanum suaveolens Species 0.000 description 2
- 235000005619 Solanum unguiculatum Nutrition 0.000 description 2
- 235000005189 Solanum uporo Nutrition 0.000 description 2
- 240000001686 Solanum uporo Species 0.000 description 2
- 235000007375 Solanum viride Nutrition 0.000 description 2
- 244000066511 Solanum xanthocarpum Species 0.000 description 2
- 235000017622 Solanum xanthocarpum Nutrition 0.000 description 2
- 206010043189 Telangiectasia Diseases 0.000 description 2
- 208000009056 Telangiectasis Diseases 0.000 description 2
- SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 description 2
- 229960001727 Tretinoin Drugs 0.000 description 2
- 239000006096 absorbing agent Substances 0.000 description 2
- 239000003637 basic solution Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000002708 enhancing Effects 0.000 description 2
- 229940030275 epigallocatechin gallate Drugs 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 230000001744 histochemical Effects 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 108010045030 monoclonal antibodies Proteins 0.000 description 2
- 102000005614 monoclonal antibodies Human genes 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 230000001590 oxidative Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 230000002829 reduced Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000037380 skin damage Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 231100001005 telangiectasia Toxicity 0.000 description 2
- 230000001225 therapeutic Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 229940117893 Apigenin Drugs 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 235000010301 Carolina horsenettle Nutrition 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 235000015844 Citrullus colocynthis Nutrition 0.000 description 1
- 240000002694 Clidemia hirta Species 0.000 description 1
- 235000014277 Clidemia hirta Nutrition 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 229940109262 Curcumin Drugs 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010014970 Ephelide Diseases 0.000 description 1
- 210000002615 Epidermis Anatomy 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 229940045109 Genistein Drugs 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N Genistin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 208000000069 Hyperpigmentation Diseases 0.000 description 1
- 208000003367 Hypopigmentation Diseases 0.000 description 1
- 108010077451 IGG-horseradish peroxidase Proteins 0.000 description 1
- 108090001095 Immunoglobulin G Proteins 0.000 description 1
- 102000004851 Immunoglobulin G Human genes 0.000 description 1
- 206010024217 Lentigo Diseases 0.000 description 1
- 210000000265 Leukocytes Anatomy 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 210000001616 Monocytes Anatomy 0.000 description 1
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 1
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 235000000255 Solanum americanum Nutrition 0.000 description 1
- 241000047322 Solanum linnaeanum Species 0.000 description 1
- 240000002307 Solanum ptychanthum Species 0.000 description 1
- 235000000341 Solanum ptychanthum Nutrition 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 240000001016 Solanum tuberosum Species 0.000 description 1
- 240000004609 Solanum undatum Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004103 aerobic respiration Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229930013930 alkaloids Natural products 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000058 anti acne agent Substances 0.000 description 1
- 230000000844 anti-bacterial Effects 0.000 description 1
- 230000001139 anti-pruritic Effects 0.000 description 1
- 230000002682 anti-psoriatic Effects 0.000 description 1
- 230000001153 anti-wrinkle Effects 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 235000010310 bull nettle Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 231100000762 chronic effect Toxicity 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000001186 cumulative Effects 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 230000002354 daily Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000010313 devils tomato Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000007905 drug manufacturing Methods 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- 231100001006 hyperpigmentation Toxicity 0.000 description 1
- 230000003425 hypopigmentation Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002757 inflammatory Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 230000003902 lesions Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 108091008117 polyclonal antibodies Proteins 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 230000000770 pro-inflamatory Effects 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000004881 tumor cells Anatomy 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 239000003357 wound healing promoting agent Substances 0.000 description 1
- 230000002034 xenobiotic Effects 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/92—Oral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/004—Aftersun preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Abstract
598234 Disclosed is the use of a water-soluble extract from a plant of Solanum genus in the manufacture of a medicament for treating cutaneous photodamage or inflammation, wherein said water-soluble extract comprises solamargine and solasonine. Further disclosed is the use of a water-soluble extract from a plant of Solanum genus, wherein said water-soluble extract comprises solamargine and solasonine in the manufacture of a cosmetic composition. ct from a plant of Solanum genus, wherein said water-soluble extract comprises solamargine and solasonine in the manufacture of a cosmetic composition.
Description
TREATMENT AND/OR PREVENTION OF INFLAMMATION AND
CUTANEOUS PHOTODAMAGE AND PHOTOPROTECTION OF THE SKIN
WITH A WATER-SOLUBLE EXTRACT FROM PLANT OF SOLANUM
GENUS
This application claims priority of Taiwanese application no. 100116659,
filed on May 12, 2011.
The present invention relates generally to the use of a water-soluble
extract from a plant of Solanum genus in the manufacture of a medicament.
Also described herein is a pharmaceutical composition for preventing and
treating inflammation and cutaneous photodamage, which contains a
water-soluble extract from a plant of Solanum genus. The composition also
has a photoprotective effect, and can be used as a cosmetic composition.
In aerobic organisms, oxygen is utilized in aerobic respiration, thereby
producing reactive oxygen species (ROS) and free radicals. Ultraviolet (UV),
ionizing radiation, and certain medications or xenobiotics will also stimulate
production of ROS and free radicals. ROS and free radicals are likely to react
with components within the cell (e.g., DNA, protein and lipids etc.) due to
instability thereof, thereby resulting in oxidative damage to cells and tissues.
In general, antioxidant enzymes in organisms form an interacting
network to protect cells and tissues from oxidative damage. Oxidative stress
forms when ROS and free radicals exceed the antioxidant capacity provided
by the interacting network of the cells or tissues. It has been reported that
oxidative stress plays an important role in the pathological process of
inflammation and photodamage (Simon R. et al (2010), Free radical biology &
Medicine, 49:1603-1616; Afaq F. et al. (2006), Experimentla Dematology,
:678-684).
Inflammation is a protective response of cells or tissues to pathogen and
external stressful stimuli. During inflammation, the cells or tissues at a site of
injury will stimulate the expression of specific genes through NF-kB, followed
by an increased expression of chemokines, thereby leading to the
accumulation of polynuclear leukocytes, monocytes, macrophages and mast
cells at the site of injury (i.e., infiltration). The recruited macrophages will be
activated by lipopolysaccharides (LPS) that are expressed on a surface of a
pathogen. The activated macrophages will induce the expression of
proinflammatory genes (including cylooxygenase-2 gene, COX-2, and
inducible nitric oxide synthase gene, iNOS) to reinforce inflammatory
response. In addition, the activated macrophages release ROS and free
radicals to kill pathogens. However, prolonged inflammatory response leads
to oxidative stress and damage due to excess accumulation of ROS and free
radicals, thereby resulting in chronic inflammation and ultimately potentiating
the possibility of chronic illnesses or cancer.
Photodamage occurs when skin of an organism is exposed to ultraviolet
(especially ultraviolet-B, UV-B), leading to skin damage. Exposure to UV
radiation will accelerate the accumulation of ROS and free radicals in skin
cells, increase oxidative stress to the skin cells and induce expression of
matrix metalloproteinases (MMP), thereby resulting in oxidative
photodamage. Symptoms of oxidative photodamage include: telangiectasia,
thinning of epidermis, reduction in collagen fiber and elastic fiber, dryness,
wrinkle formation, inflammatory cell infiltration, premature skin aging and skin
pathologic change.
In recent years, phytochemicals or phytochemopreventive agents
derived from plants have been proven to have antioxidant, anti-inflammatory
properties and improve photodamage. Examples of the phytochemical
include: green tea polyphenols (GTPs), epigallocatechin gallate (EGCG),
genistein, resveratrol, curcumin, apigenin, lycopene, etc. (Adhami V.M. et al
(2008), Photochem. Photobiol., 84:489-500). The phytochemicals have been
proven to be safer for clinical application without undesired side effects, and
have caught attention in the field of medical research.
Plants of Solanum genus include Solanum incanum L., synonymous with
Solanum undatum, Solanum incanum Ruiz. & Pav., Solanum coagulans
Forsskal;bitter apple in English), Solanum indicum, Solanum nigrum (Long
kui in Chinese;black nightshade in English), Solanum capsicastrum (false
jerusalem cherry in English), Solanum xanthocarpum, Solanum melongena,
Solanum coagulans, Solanum tuberosum, Solanum sodomeum (apple of
Sodom in Australia), Solanum turburosum, Solanum aculeastrum, Solanum
lycocarpum, Solanum khasianum, Solanum suaveolens, Solanum uporo,
Solanum abutiloides, Solanum coccineum, Solanum unguiculatum, Solanum
robustum, Solanum anguivi, Solanum platanifolium, Solanum mammosum,
etc. It is known that steroidal alkaloids can be extracted from the Solanum
genus, and commonly include solasonine and solamargine.
US 7,078,063 B2 issued to the inventors of the present invention
discloses a water-soluble extract from a plant of Solanum genus, especially
Solanum incanum L., which includes at least 60 wt% of solasonine and
solamargine., and a method for preparing the water-soluble extract. The
patent is hereby incorporated by reference in its entirety.
In the aforesaid US patent, the inventors found that the water-soluble
extract can inhibit the growth of tumor/cancer cells (specifically liver tumor
cells, lung cancer cells, and breast cancer cells). In this invention, the
inventors unexpectedly found that the water-soluble extract effectively cure
and/or prevent inflammation and cutaneous photodamage.
Summary of the Invention
Therefore, in one aspect, this invention provides the use of a
water-soluble extract from a plant of Solanum genus in the manufacture of a
medicament for treating cutaneous photodamage, wherein said water-soluble
extract comprises solamargine and solasonine.
In another aspect the invention provides the use of a water-soluble
extract from a plant of Solanum genus, wherein said water-soluble extract
comprises solamargine and solasonine in the manufacture of a cosmetic
composition.
In another aspect the invention provides the use of a water-soluble
extract from a plant of Solanum genus in the manufacture of a medicament
for treating inflammation, wherein said water-soluble extract comprises
solamargine and solasonine.
Also described herein is a pharmaceutical composition for preventing
and treating cutaneous photodamage, comprising a water-soluble extract
from a plant of Solanum genus, the water-soluble extract comprising
solamargine and solasonine.
Also described herein is a method for preventing and treating cutaneous
photodamage, comprising applying to a subject in need of such treatment a
water-soluble extract from a plant of Solanum genus, the water-soluble
extract comprising solamargine and solasonine.
Also described herein is the use of a water-soluble extract from a plant of
Solanum genus in the manufacture of a medicament for preventing and
treating cutaneous photodamage, the water-soluble extract comprising
solamargine and solasonine.
Also described herein is a cosmetic composition, comprising a
water-soluble extract from a plant of Solanum genus, the water-soluble
extract comprising solamargine and solasonine.
Also described herein is a pharmaceutical composition for preventing
and treating inflammation, comprising a water-soluble extract from a plant of
Solanum genus, said water-soluble extract comprising solamargine and
solasonine.
Also described herein is a method for preventing and treating
inflammation, comprising applying to a subject in need of such treatment a
water-soluble extract from a plant of Solanum genus, the water-soluble
extract comprising solamargine and solasonine.
Also described herein is the use of a water-soluble extract from a plant of
Solanum genus in the manufacture of a medicament for preventing and
treating inflammation, the water-soluble extract comprising solamargine and
solasonine.
Certain statements that appear below are broader than what appears in
the statements of the invention above. These statements are provided in
the interests of providing the reader with a better understanding of the
invention and its practice. The reader is directed to the accompanying claim
set which defines the scope of the invention.
Brief Description of the Drawings
Other features and advantages of the present invention will become
apparent in the following detailed description of the preferred embodiments of
the invention, with reference to the accompanying drawings in which:
Figure 1 is a western blot, showing COX-2 expression in RAW264.7 cell
after LPS-induced inflammatory response. The cells in normal control group
were not treated with LPS and a water-soluble extract from a plant of
Solanum genus, whereas cells in pathological control group were treated with
100ng/mL of LPS. Experimental groups 1-6 were treated with various
concentrations of the water-soluble extract (0.01, 0.05, 0.1, 0.5, 1 and 5 μ
g/mL) along with 100ng/mL of LPS;
Figure 2 shows transepidermal water loss (TEWL) of dorsal skin of
HRS/J hairless mice in each of normal control group, pathological control
group, and experimental groups 1 and 2 after 6 weeks of UV-B radiation.
HRS/J hairless mice in normal control group did not receive any treatment
including UV-B radiation and the water-soluble extract. HRS/J hairless mice
in pathological control group were exposed to UV-B radiation and were not
treated with the water-soluble extract. In experimental group 1, HRS/J
hairless mice were exposed to UV-B radiation and were treated with Solanum
incanum L. solution containing the water-soluble extract. In experimental
group 2, HRS/J hairless mice were exposed to UV-B radiation and were
treated with Solanum incanum L. gel containing the water-soluble extract;
Figure 3 is a western blot showing expressions of NF-kB, COX-2 and
iNOS from dorsal skin tissue of HRS/J hairless mice after the 60 week
experimental period. HRS/J hairless mice in normal control group did not
receive any treatment including UV-B radiation and the water-soluble extract.
HRS/J hairless mice in pathological control group were exposed to UV-B
radiation and were not treated with the water-soluble extract. In experimental
group 2, HRS/J hairless mice were exposed to UV-B radiation and were
treated with Solanum incanum L. gel containing the water-soluble extract;
Figure 4 shows an immmunohistochemistry of NF-kB expression on
dorsal skin tissue from HRS/J hairless mice at the end of 60 weeks after the
first time of UV-B radiation. HRS/J hairless mice in normal control group did
not receive any treatment including UV-B radiation and the water-soluble
extract. HRS/J hairless mice in pathological control group were exposed to
UV-B radiation and were not treated with the water-soluble extract. In
experimental group 2, HRS/J hairless mice were exposed to UV-B radiation
and were treated with Solanum incanum L. gel containing the water-soluble
extract;
Figure 5 shows a toluidine blue stain of dorsal skin tissue from HRS/J
hairless mice at the end of the 60week experimental period. HRS/J hairless
mice in normal control group did not receive any treatment including UV-B
radiation and the water-soluble extract. HRS/J hairless mice in pathological
control group were exposed to UV-B radiation and were not treated with the
water-soluble extract. In experimental group 2, HRS/J hairless mice were
exposed to UV-B radiation and were treated with Solanum incanum L. gel
containing the water-soluble extract. Arrows indicate the locations of
infiltrated mast cells;
Figure 6 is a bar diagram showing average mast cell number from dorsal
skin tissue of HRS/J hairless mice in normal control group, pathological
control group, and experimental group 2 after the 60 week experimental
period. HRS/J hairless mice in normal control group did not receive any
treatment including UV-B radiation and the water-soluble extract. HRS/J
hairless mice in pathological control group were exposed to UV-B radiation
and were not treated with the water-soluble extract. In experimental group 2,
HRS/J hairless mice were exposed to UV-B radiation and were treated with
Solanum incanum L. gel containing the water-soluble extract. “*” indicates
p<0.05 between experimental group 2 and normal control group. “***”
indicates p<0.01 between experimental group 2 and pathological control
group. “###” indicates p<0.001 between pathological control group and
normal control group;
Figure 7 is a plot showing average tumor number in HRS/J mice formed
at various time points during the 60 week experimental period. HRS/J
hairless mice in pathological control group had photodamage induced by
UV-B radiation and were not treated with the water-soluble extract. HRS/J
hairless mice in experimental group 1 were exposed to UV-B radiation and
were treated with Solanum incanum L. solution containing the water-soluble
extract. In experimental group 2, HRS/J hairless mice were exposed to UV-B
radiation and were treated with Solanum incanum L. gel containing the
water-soluble extract. “*” indicates p<0.05 between experimental group 2
and pathological control group. “**” indicates p<0.01 between experimental
group 2 and pathological control group;
Figure 8 is a plot showing average tumor size in HRS/J hairless mice at
various time points during the 60 week experimental period. HRS/J hairless
mice in pathological control group had photodamage induced by UV-B
radiation and were not treated with the water-soluble extract. HRS/J hairless
mice in experimental group 1 were exposed to UV-B radiation and were
treated with Solanum incanum L. solution containing the water-soluble
extract. HRS/J hairless mice in experimental group 2 were exposed to UV-B
radiation and were treated with Solanum incanum L. gel containing the
water-soluble extract. “#” indicates p<0.05 between experimental group 1 and
pathological control group. “##” indicates p<0.01 between experimental group
1 and pathological control group. “###” indicates p<0.001 between
experimental group 1 and pathological control group. “**” indicates p<0.01
between experimental group 2 and pathological control group. “***” indicates
p<0.001 between experimental group 2 and pathological control group;
Figure 9 is a bar diagram showing recovery time in pinch test on HRS/J
hairless mice after the 60 week experimental period. HRS/J hairless mice in
normal control group did not receive any treatment including UV-B radiation
and the water-soluble extract. HRS/J hairless mice in pathological control
group were exposed to UV-B radiation and were not treated with the
water-soluble extract. In experimental group 2, HRS/J hairless mice were
exposed to UV-B radiation and were treated with Solanum incanum L. gel
containing the water-soluble extract. “***” indicates p<0.001 between
experimental group 2 and pathological control group. “###” indicates p<0.001
between pathological control group and normal control group;
Figure 10 shows images of elastic fibers of dorsal skin tissue stained
with resorcin-fuchsin solution, Weigert’s iron hematoxylin and van Gieson
solution. HRS/J hairless mice in pathological control group had photodamage
induced by UV-B radiation and were not treated with the water-soluble extract.
In experimental group 2, HRS/J hairless mice were exposed to UV-B
radiation and were treated with Solanum incanum L. gel containing the
water-soluble extract. Arrows indicate the locations of elastic fiber
denaturation;
Figure 11 shows average tumor number in HRS/J hairless mice over the
experimental period. HRS/J hairless mice were exposed to UV-B radiation
and were treated with AIROL vanishing cream in tretinoin group. In Solanum
incanum L. gel group, HRS/J hairless mice were exposed to UV-B radiation
and were treated with Solanum incanum L. gel containing the water-soluble
extract;
Figure 12 is a graph showing transepidermal water loss (TEWL) over the
experimental period. HRS/J hairless mice in pathological control group were
exposed to UV-B radiation and were not treated with the water-soluble extract.
HRS/J hairless mice in tretinoin group were exposed to UV-B radiation and
were treated with AIROL vanishing cream. In Solanum incanum L. gel group,
HRS/J hairless mice were exposed to UV-B radiation and were treated with
Solanum incanum L. gel containing the water-soluble extract. “*” indicates
p<0.05 between tretinoin group and Solanum incanum L. gel group; and
Figure 13 is a graph showing water content of dorsal skin from HRS/J
hairless mice over the experimental period. HRS/J hairless mice in
pathological control group had photodamage induced by UV-B radiation and
were not treated with the water-soluble extract. In tretinoin group, HRS/J
hairless mice were exposed to UV-B radiation and were treated with AIROL
vanishing cream. In Solanum incanum L. gel group, HRS/J hairless mice
were exposed to UV-B radiation and were treated with Solanum incanum L.
gel containing the water-soluble extract. “*” indicates p<0.05 between
tretinoin group and Solanum incanum L. gel group.
It is to be understood that, if any prior art publication is referred to herein,
such reference does not constitute an admission that the publication forms a
part of the common general knowledge in the art, in Taiwan or any other
country.
For the purpose of this specification, it will be clearly understood that the
word “ comprising” means “including but not limited to”, and that the words
“comprises,” “contain” and variants thereof have a corresponding meaning.
Unless otherwise defined, all technical and scientific terms used herein
have the meaning commonly understood by a person skilled in the art to
which this invention belongs. One skilled in the art will recognize many
methods and materials similar or equivalent to those described herein, which
could be used in the practice of this invention. Indeed, this invention is in no
way limited to the methods and materials described. For clarity, the following
definitions are used herein.
Described herein is a pharmaceutical composition for preventing and
treating inflammation, which includes a water-soluble extract from a plant of
Solanum genus. The water-soluble extract comprises solamargine and
solasonine. Preferably, the water-soluble extract comprises at least 60 wt%
solamargine and solasonine, more preferably, 60 wt%-90 wt% of solamargine
and solasonine.
A process for preparing the water-soluble extract has been disclosed in
US 7,078,063 B2, and includes the following steps:
(a) subjecting a plant material of a plant of Solanum genus to an extraction
treatment using an acidic aqueous solution with a pH value of 3~5, such
that an aqueous solution is obtained;
(b) adjusting the pH value of the aqueous solution obtained in step (a) to pH
8~10 with a base, such that a precipitate is formed;
(c) washing the precipitate formed in step (b) with water, followed by drying,
such that a dried product is obtained;
(d) admixing the dried product obtained in step (c) with chloroform, followed
by addition of a suitable amount of a 100% alcohol, such that a
chloroform-alcohol mixture is formed;
(e) mixing the chloroform-alcohol formed in step (d) with a water/alcohol
solution having a predetermined water/alcohol ratio, such that a mixture
containing a chloroform-based layer and a non-chloroform-based layer is
obtained;
(f) removing the chloroform-based layer from the mixture obtained in step (e),
followed by addition of a suitable amount of water; and
(g) obtaining a supernatant from the resultant mixture of step (f), followed by
drying the supernatant, wherein the resultant dried product is able to be
directly dissolved in water to form a yellowish clear and transparent
aqueous solution.
Preferably, the water-soluble extract of a plant of Solanum genus has
been obtained at least from the fruit, root, stem and leaf of the plant of
Solanum genus. The plant of Solanum genus has been chopped in a
preliminary treatment. In a preferred embodiment, the plant material used in
step (a) is the fruit of the plant of Solanum genus.
The inventors found that certain factors might affect the content and
proportion of solasonine and solamargine in the water-soluble extract
obtained using the aforesaid process. These factors include the species of
the plant of Solanum genus and the part(s) of the plant used in the extracting
process, as well as the types of alcohol and base used. Therefore, a skilled
artisan can prepare a desired water-soluble extract by selecting suitable
species of the plant, in conjunction with appropriate operating conditions.
Preferably, the water-soluble extract is obtained from a plant of Solanum
genus selected from the group consisting of Solanum incanum L., Solanum
indicum, Solanum nigrum, Solanum capsicastrum , Solanum xanthocarpum,
Solanum melongena, Solanum coagulans, Solanum tunigrum, Solanum
sodomeum, Solanum turburosum, Solanum aculeastrum, Solanum
lycocarpum, Solanum khasianum, Solanum suaveolens, Solanum uporo,
Solanum abutiloides, Solanum coccineum, Solanum unguiculatum, Solanum
robustum, Solanum anguivi, Solanum platanifolium and Solanum
mammosum. In a preferred embodiment, the water-soluble extract is
obtained from Solanum incanum L..
In preliminary experiments, in vitro data have shown that the
water-soluble extract from Solanum genus can inhibit inflammatory response
induced by LPS. It has also been proven that, after hairless mice with UV-B
induced inflammation are treated with the water-soluble extract from
Solanum genus, the expression of NF-kB, COX-2 and iNOS on skin tissue
thereof was markedly decreased, together with an alleviation of mast cell
infiltration and inflammatory response.
Therefore, described herein is a method for preventing and treating
inflammation, comprising applying to a subject in need of such treatment the
water-soluble extract or the pharmaceutical composition.
The administration route of the aforesaid pharmaceutical composition
described herein comprises, but is not limited to oral, topical and parenteral
routes.
The pharmaceutical composition described herein can be formulated
into an oral dosage form using technology well known to a skilled artisan.
Examples of the oral dosage form include, but are not limited to: aseptic
power, tablet, troche, lozenge, pellet, capsule, dispersible powder or granule,
solution, suspension, emulsion, syrup, elixir, slurry, etc.
The pharmaceutical composition described herein can further include a
pharmaceutically acceptable carrier that is widely employed in
drug-manufacturing technology.
The pharmaceutically acceptable carrier comprises one or more
reagents, including: solvent, buffer, emulsifier, suspending agent,
decomposer, disintegrating agent, dispersing agent, binding agent, excipient,
stabilizing agent, chelating agent, preservative, wetting agent, lubricant,
diluent, absorption delaying agent, liposome, sweetening agent, flavoring
agent, coloring agent, etc. The choice and amount of the pharmaceutically
acceptable carrier are within the expertise of those skilled in the art.
The pharmaceutically acceptable carrier comprises one or more
reagents including, for example, water, normal saline, phosphate buffered
saline (PBS), glucose containing solution, aqueous solution containing
alcohol (for example, ethanol, propanediol, glycol, mannitol, etc.), oil (for
example, peanut oil, olive oil, sesame oil, castor oil, cottonseed oil, soybean
oil, etc.), glycerol, organic solvent and liposome. In an embodiment described
herein, the solvent is water.
The pharmaceutical composition described herein can be formulated
into a suitable dosage form for topical administration using technology well
known to those skilled in the art, which includes, but is not limited to, external
preparations, effervescent tablets, suppositories, and the like.
In a preferred embodiment described herein, the pharmaceutical
composition described herein is formulated into an external preparation in a
gel form by admixing the water-soluble extract with a base that is well known
and commonly used in the art.
As described herein, the suitable base may include one or more of the
following additives: water, alcohols, glycol, hydrocarbons (such as petroleum
jelly and white petrolatum), waxes (such as paraffin and yellow wax),
preserving agents, antioxidants, surfactants, absorption enhancers,
stabilizing agents, gelling agents (such as carbopol 974P, microcrystalline
cellulose and carboxymethylcellulose), active agents, humectants, odor
absorbers, fragrances, pH adjusting agents, chelating agents, emulsifiers,
occlusive agents, emollients, thickeners, solubilizing agents, penetration
enhancers, anti-irritants, colorants and propellants etc. The choice and
amount of these additives are within the expertise of those skilled in the art.
The dosage and frequency of administration of this pharmaceutical
composition may vary depending on the following factors: the severity of the
disease to be treated, the route of administration, and the weight, age,
physical condition and response of the subject to be treated. For instance, the
daily dosage of the pharmaceutical composition for topical administration as
described herein may be 10-20 mg/cm of the lesion area and one to six
times per day. The dosage of this pharmaceutical composition for oral
administration may be 1-30 mg/Kg, 1-4 times a day.
The water-soluble extract from the plant of Solanum genus has been
proven to alleviate skin pathological change induced by UV-B-induced
cutaneous photodamage on hairless mice. In addition, it can effectively
improve skin elasticity and solar elastosis, while maintaining
moisture-retaining capacity at the same time.
Therefore, described herein is a pharmaceutical composition for treating
and/or preventing cutaneous photodamage, which comprises the
water-soluble extract from a plant of Solanum genus as described above.
Also described herein is a method for preventing and treating cutaneous
photodamage, comprising applying to a subject in need of such treatment the
aforesaid water-soluble extract or the pharmaceutical composition.
As used herein, the term “cutaneous photodamage” indicates skin
damage caused by exposure of skin to sunlight or UV light (especially, UV-B).
The cutaneous photodamage comprises, but is not limited to : thinning of the
skin, skin atrophy, decrease in collagen fiber and elastic fiber, elastosis, loss
of skin elasticity, dryness, wrinkle formation, inflammatory cell infiltration,
premature skin aging, vascular change (such as diffuse erythema,
ecchymosis, or telangiectasia), pigmentary change (such as lentigines,
freckles, hypopigmentation or hyperpigmentation), comedone, cyst and skin
pathological change.
As described herein, the administration route, dosage and
pharmaceutically acceptable carrier are similar to those used in the
pharmaceutical composition for preventing and treating inflammation. In a
preferred embodiment, the pharmaceutical composition is formulated into
topical form for administration onto the skin.
Due to prevention/protection of cutaneous photodamage of the
water-soluble extract, one can predict that the water-soluble extract can be
used as a cosmetic component to prepare a cosmetic composition.
Therefore, described herein is a cosmetic composition with
photoprotective effect, which comprises the water-soluble extract as
described above.
As used herein, the term “photoprotective” indicates to block or alleviate
adverse clinical, histological and immunological effects caused by the sun or
ultraviolet. These effects include acute reactions (such as erythema and
inflammation) and chronic effects (such as elastosis and wrikinle formation).
As described herein, the cosmetic compositions further comprise
cosmetically acceptable adjuvant that is widely employed in
cosmetic-manufacturing technology.
The acceptable adjuvant comprises one or more reagents including
solvent, gelling agent, activating agents, preservatives, antioxidants,
screening agent, chelating agent, surfactants, coloring agent, thickening
agent, filler, fragrance and odor absorbent. The choice and amount of these
additives are within the expertise of those skilled in the art.
The cosmetic composition described herein can be prepared using
technology well known to a skilled artisan into the form of skincare, haircare
or makeup products. The form includes, but is not limited to, aqueous solution,
emulsion, gel, ointment, cream, mask, patch, powder, aerosol, spray, lotion,
sunblock and other body cleansing products.
The cosmetic composition described herein can be used with the
following agents: whitening agents, humectants, bactericides, ultraviolet
absorbers, anti-acne agent, antipruritic, antihyperkeratolytic agents,
antipsoriatic agents, antiager, antiwrinkle agents, antiseborrheic agents,
self-tanning agents and wound-healing agents. The choice and amount of
these agents are within the expertise of those skilled in the art.
Examples
Experimental Materials:
1. Preparations of water-soluble extract from Solanum incanum L. and
Solanum incanum L. solution containing the water-soluble extract:
The water-soluble extract from Solanum incanum L. was prepared based
on the procedure disclosed in Example 1 of US 7,078,063 B2. Specifically,
500 g of ripe fruit of Solanum incanum L. was ground subsequent to addition
of 1000 ml pure water. To the resultant aqueous mixture, 99.5% of acetic acid
was added dropwise to adjust the pH value to 4.0, followed by shaking at
room temperature for 12 hrs. A supernatant was obtained by centrifuging the
aqueous mixture, and 33% NH OH basic solution was added thereto
dropwise to adjust the pH value of the supernatant to 9.0, and a precipitate
was formed. The precipitate was obtained by conducting centrifugation at
4,500 rpm (Beckman Coulter, Avanti J-25, JA-14 Rotor), and the residual
basic solution present therein was removed by washing the precipitate with
water, followed by centrifugation at 4,500 rpm. The precipitate thus obtained
was suspended in distilled water and subjected to lyophilization (Virtis,
Freezemobile 12ES) to get 5 g of dried powder.
2 g of the dried powder was dissolved in 50 ml chloroform in reagent
grade, followed by addition of 40 ml of 100% methanol and was shaken to
form a uniform suspension. A supernatant was obtained by centrifugation at
4,500 rpm or filtration. 70 ml of methanol:water solution (1:1) was added to
the supernatant and mixed well. The mixture obtained was centrifuged at
12,000 rpm for 10 min. The resultant supernatant was taken out, and 120 ml
distilled water was added thereto and shaken well. Meanwhile, the
supernatant became murky. The supernatant was further centrifuged at
12,000 rpm for 10 min so as to remove the precipitate. The resultant
supernatant was subjected to decompress concentrating under reduced
pressure at 55° C to remove methanol, followed by lyophilization to obtain
dried powder of the water-soluble extract.
The water-soluble extract was dissolved in sterilized water to obtain a
Solanum incanum L. solution for further use in experiments described below.
2. Preparation of Solanum incanum L. gel containing the water-soluble
extract:
4 g of carbopol 974P, which was used as a gelling agent and is
commercially available from Lubrizol Advanced Materials, Inc., KY 40258,
USA, was dissolved in 50g pure water, followed by sequentially adding 30g
propylene glycol and 7 g of the dried powder of the water-soluble extract
obtained from the section of “1. Preparations of water-soluble extract from
Solanum incanum L. and Solanum incanum L. solution containing the
water-soluble extract” under “Experimental Materials” and mixing well. The
mixture was heated in a heating vessel at a temperature of 50℃-60℃ for 20
minutes, followed by cooling at room temperature. The cooled mixture was
added with trienthanolamine to adjust pH to 7.0±0.5. Subsequently, water
was added until the total weight of the mixture reached 100g, thereby
obtaining a gel containing 7% (w/w) of the water-soluble extract (hereinafter
referred to as Solanum incanum L. gel).
3. Animal model
HRS/J hairless mice (6-8 weeks old, body weight 20-22g) were
purchased from Jackson Laboratory (Bar Harbor, USA). The mice were kept
in a room with 12 hr/12 hr light/dark cycle, temperatures of 21-22℃, and
-70% humidity. Diet and water were sufficient and accessible to the mice at
all times. All animal experiments were conducted according to Guide for the
Care and Use of Laboratory Animals of National Institute of Health (NIH).
General Methods:
1. Analysis of protein products:
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
and western blot were used for protein analysis in this invention. Apparatus
and reagents for SDS-PAGE and western blot are as follows:
a. Vertical electrophoresis system (Hoefer SE600, GE Healthcare) were
used for SDS-PAGE analysis.
b. Polyvinvylidene difluoride membrane (PVDF, Millipore) and semi-dry
blotters (Hoefer TE70X, GE Healthcare) were used for protein transfer.
c. Primary and secondary antibodies used in western blot method are listed
in Table 1.
d. Proteins were visualized by chemiluminescence staining using
ImmobilonTM Western Chemiluminescent HRP Substrate (Millipore, Cat
No. WBKLS0500), followed by detection on autoradiography films
(Kodak Biomax, Kodak Cat. No. 1788207).
Table 1. Primary and secondary antibodies used in western blot analysis
Target Primary antibody Secondary antibody
protein
COX-2 Mouse anti COX-2 monoclonal Sheep anti mouse
antibody (BD Bioscience, Cat. No. IgG-horseradish peroxidase
610203) (HRP) antibody (Amersham,
Cat. No. NA931)
NF-κB Rabbit anti NF-κB monoclonal antibody Donkey anti rabbit IgG-HRP
(Abcam, Cat. No. Ab7970) antibody (Amersham, Cat. No.
NA934)
iNOS Rabbit anti iNOS polyclonal antibody Donkey anti rabbit IgG-HRP
(Santa Cruz, Cat. No. Sc-651) antibody
β-actin Mouse anti β-actin monoclonal Sheep anti mouse IgG-HRP
antibody (Sigma, Cat. No. A5441) antibody
GAPDH Mouse anti GAPDH monoclonal Sheep anti mouse IgG-HRP
antibody (Chemicon, Cat. No. Mab374) antibody
2. Induction of inflammation and photodamage:
Dorsal skin of each of the HRS/J mice was exposed to UV-B radiation
three times a week for 14 weeks to induce inflammatory response and
photodamage. The UV-B radiation was carried out using BLX-312 ultraviolet
crosslinker (BIO-LINK, Vilber Lourmat, France), which is equipped with 6x8W
T-8M UV-B lamp (312 nm).The single dosage of UV-B radiation for each
exposure, the UV-B dosage for one week (dosage/wk), and the cumulative
dosage are listed in Table 2.
Table 2.
Experimental
Single UV-B dosage Accumulated
time point Dosage/wk (mJ/cm )
(mJ/cm ) dosage (mJ/cm )
(wk)
1 36 108 108
2 54 162 270
3 72 216 486
4 90 270 765
108 324 1080
6 126 378 1458
7 144 432 1890
8 162 486 2376
9 180 540 2916
216 594 3510
11 216 648 4158
12 216 648 4806
13 216 648 5454
14 216 648 6102
3. Tissue slice:
Tissues (harvested at room temperature) were fixed in 4%
paraforaldehyde in PBS for at least 12 hrs, followed by ethanol dehydration.
The dehydrated tissues were embedded in paraffin and sliced to obtain
longitudinal sections.
4. Statistical analysis:
Results are shown as mean ± standard error mean (SEM). All statistical
data analyses were performed by Student’s t-test (2-tailed). P<0.05 is
considered statistically significant.
Example 1: Evaluation of in vitro anti-inflammatory effect of the
water-soluble extract from Solanum incanum L.
Murine macrophage cell line RAW264.7 that was subjected to
lipopolysaccharides (LPS)-induced inflammation was used to determine the
anti-inflammatory effect of the water-soluble extract from Solanum incanum
RAW264.7 cells (purchased from American Type Culture Collection,
ATCC, TIB-71) were seeded at a density of 1x10 cells/well (6-well plate) in
Dulbecco’s Modified Eagle’s Medium (DMEM) (HyClone SH 30022.01, Logan,
Utah, USA) with 10% fetal bovine serum (FBS), 4mM L-glutamine and 4.5 g/L
glucose (without sodium pyruvate), and incubated in a 37℃, 5% CO
incubator. The cells were divided into three groups: normal control group,
pathological control group and experimental groups (experimental groups 1,
2, 3, 4, 5 and 6). After 72hrs of incubation, the pathological control group was
changed to be incubated in fresh DMEM medium containing 100ng/mL of
LPS (Escherichia coli serotype 0111:B4, Sigma), and the experimental
groups were incubated in fresh DMEM media containing 100ng/mL of LPS
and different concentrations of the water-soluble extracts obtained from the
section of “1. Preparations of water-soluble extract from Solanum incanum L.
and Solanum incanum L. solution containing the water-soluble extract” under
“Experimental Materials”. The concentrations of the water-soluble extracts for
experimental groups 1, 2, 3, 4, 5 and 6 were respectively 0.01, 0.05, 0.1, 0.5,
1 and 5 μg/mL. The normal control group was still incubated in DMEM with
% FBS, 4mM L-glutamine and 4.5 g/L glucose (without sodium pyruvate).
After 24hrs of incubation (in a 37℃, 5% CO incubator), the medium in
each well was removed followed by addition of 100μL T-PER reagent
(purchased from PIERCE) and mixing to obtain a cell mixture. The cell
mixture was placed in a centrifugation tube and shaken for 5 min followed by
cooling on ice for 30 min. Subsequently, the cell mixture was centrifuged at
14,000 rpm for 10 min at 4℃ and a supernatant was collected as a protein
sample for further analyses.
The resultant protein sample was subjected to COX-2 western blot
analysis using the method described in the section of “1. Analysis of protein
products” under “General Methods”. β-actin was used as an internal control.
Figure 1 is a western blot showing COX-2 expression in RAW264.7 cells.
As shown in Figure 1, COX-2 expression was markedly increased in the
pathological control group when compared to the normal control group, which
indicates a successful induction of inflammation by LPS in RAW264.7 cells. A
decreased expression of COX-2 was observed in experimental group 1-6
when compared to the pathological control group, and the decreased
expression is more obvious when a higher concentration of water-soluble
extract was added. These data demonstrate that the water-soluble extract
from Solanum incanum L. can inhibit LPS-induced inflammation in vitro, and
the effect of the water-soluble extract on anti-inflammatory response is
dose-dependent.
Example 2: Evaluation of the therapeutic effects of the Solanum
incanum L. solution and the Solanum incanum L. gel on hairless mice
with UV-B-induced inflammation
HRS/J hairless mice was randomly grouped into normal control group,
pathological control group and two experimental groups (i.e. experimental
group 1 and 2) (n=4/group). HRS/J hairless mice in normal control group did
not receive any UV-B radiation. The mice in pathological control group and
two experimental groups were induced inflammation using the procedure as
described in the section of “2. Induction of inflammation and photodamage”
under “General Methods”.
Starting from the initiation of UV-B radiation, HRS/J mice in experimental
group 1 was administered orally with Solanum incanum L. solution, in which
the solution was prepared as described in the section of “1. Preparations of
water-soluble extract from Solanum incanum L. and Solanum incanum L.
solution containing the water-soluble extract” under “Experimental Materials”.
These mice were administered with Solanum incanum L. solution once a day
(1500 mg/kg), 7 times a week, during a 14-week (wk) period, and were
continuously observed for 60 wks (i.e., 60 wk experimental period). On the
UV-B exposed dorsal skin of each of the HRS/J hairless mice in experimental
group 2, the Solanum incanum L. gel obtained from the section of “2.
Preparation of Solanum incanum L. gel containing the water-soluble extract”
under “Experimental Materials” was applied. The gel was applied once a day
(dosage: 10-20 mg of gel per cm2), 5 times a week, during a 14-wk period
and was observed for 60 wks. HRS/J hairless mice in normal control and
pathological control group were not treated with the Solanum incanum L.
solution nor the Solanum incanum L. gel.
After 6 wks of UV-B radiation, HRS-J hairless mice were analyzed for
Items A and B listed below. In addition, dorsal skin tissues were collected
using surgical scissors from the mice in normal control group, pathological
control group and experimental group 2 after the 60 wk experimental period.
These tissues were analyzed for Items C to E listed below.
A. Diagnosis of clinical signs:
HRS/J hairless mice were observed for any signs of inflammation, e.g.,
itching, redness, etc. after 6 wks of UV-B radiation.
B. Analysis of transepidermal water loss (TEWL)
After 6wks of UV-B radiation, TEWL was evaluated on dorsal skin of each
HRS/J hairless mouse from each group using an evaporimeter (Tewameter
TM 201R, Courage & Khazaka, Cologne, Germany).
C. Western blot analysis of NF-κB, COX-2 and iNOS
0.5 g of skin tissue was added to T-PER tissue protein extraction reagent
(Thermo Scientific, Cat. No. 78510), followed by tissue disruption by a
homogenizer (purchased from Biospec Products). The well homogenized
product was centrifuged at 15,000rpm and 4℃ for 10hrs. Supernatant was
collected for protein analysis.
The isolated protein was further used to detect NF-κB, COX-2 and iNOS by
western blot analysis according to the procedure set forth in the section of “1.
Analysis of protein products” under “General Methods”. GAPDH was used as
an internal control.
D. Immunohistochemistry stain of NF-κB
The skin tissues were sectioned into 6μm thickness using the procedure
set forth in the section of “3. Tissue slice” under “General Methods”. The
tissue sections were subjected to immunohistochemistry stain using primary
antibody rabbit anti NF-κB monoclonal antibody and donkey anti rabbit IgG
antibody conjugated with biotin (DarkoCytomation). The stained tissues were
examined under an optical microscope (Olympus BX51, Japan) under 100 to
400X magnification, and was photographed using a digital camera (Olympus
DP50, Japan).
E. Histochemistry stain of mast cells
The skin tissues were sectioned into 6μm thickness using the procedure
set forth in the section of “3. Tissue slice” under “General Methods”. The
tissue sections were subjected to histochemistry stain with toluidine blue
(Sigma, Cat No. T3260). The stained tissue sections were examined under
an optical microscope with 100 to 400X magnification, and were
photographed with a digital camera (Olympus DP50, Japan). Quantification
of mast cell number was conducted by randomly selecting 5 tissue sections,
and counting randomly 10 observing fields in each of the tissue sections.
Data are shown as mean ± SEM (p<0.05 is statistically significant).
A. Diagnosis of clinical signs
HRS/J hairless mice in pathological control group showed symptoms of
inflammation as compared to the normal control group, suggesting UV-B
radiation successfully induced inflammatory response in HRS/J hairless mice.
Experimental groups 1 and 2 showed a significant reduction in inflammatory
response when compared to the pathological control group. These data
suggest that Solanum incanum L. solution and Solanum incanum L. gel have
anti-inflammatory effects.
B. Analysis of transepidermal water loss (TEWL)
Figure 2 is a graph showing the results of TEWL of the dorsal skins of the
HRS/J hairless mice in normal control group, pathological group and
experimental groups 1 and 2. The HRS/J hairless mice from pathological
group showed an increased level of TEWL as compared to the normal control
group. This indicates that UV-B radiation induced TEWL in HRS/J hairless
mice and damaged the barrier function of stratum corneum. HRS/J hairless
mice from experimental groups 1 and 2 showed a marked decrease in TEWL
when compared to pathological control group. In all, these data suggest that
Solanum incanum L. solution and Solanum incanum L. gel can improve
stratum corneum damage and inflammation caused by UV-B radiation.
C. Western blot analysis of NF-κB, COX-2 and iNOS
Figure 3 is a western blot analysis of NF-κB, COX-2 and iNOS of dorsal
skin tissue from HRS/J hairless mice in normal control group, pathological
group and experimental group 2. The skin tissues from the pathological
control group showed an increased expression of NF-κB, COX-2 and iNOS
as compared to normal control group, suggesting that UV-B radiation induces
inflammatory response in HRS/J hairless mice. A significant reduction of
NF-κB, COX-2 and iNOS levels were observed in experimental group 2 when
compared to pathological control group. In all, these data suggest that
Solanum incanum L. gel have anti-inflammatory effects.
D. Immunohistochemistry stain of NF-κB
Figure 4 shows an immunohistochemistry stain of NF-κB expression on
dorsal skin tissue obtained from HRS/J hairless mice. As shown in Figure 4,
pathological control group showed an increased expression level in NF-κB as
compared to the normal control group, suggesting UV-B radiation induces
inflammatory response in the HRS/J hairless mice. When Solanum incanum
L. gel was applied to HRS/J hairless mice, as in experimental group 2, the
expression of NF-κB showed a significant decrease when compared to the
pathological control group. In all, these data suggest that Solanum incanum L.
gel of the present invention has anti-inflammatory effect.
E. Histochemistry stain of mast cells
Figure 5 shows a histochemistry stain of mast cells obtained from the
dorsal skin tissue of HRS/J hairless mice. As shown in Fig. 5, toluidine blue
staining revealed an extensive mast cell infiltration in dorsal skin tissue from
the pathological control group. This phenomenon was not visibly clear in the
normal control group. Apparently, mast cell infiltration was significantly
reduced in experimental group 2 as compared to the pathological control
group.
A comparison of mast cell number in each of normal control group,
pathological group and experimental group 2 is shown in Figure 6.
Experimental group 2 showed a significant decrease of mast cell number
when compared to pathological control group. These data suggest that
Solanum incanum L. gel can improve the inflammatory effect induced by
UV-B radiation in HRS/J hairless mice.
Example 3: Evaluation of the therapeutic effects of the Solanum
incanum L. solution and the Solanum incanum L. gel on hairless mice
with UV-B-induced photodamage.
HRS/J hairless mice was randomly grouped into normal control group,
pathological control group and two experimental groups (i.e., experimental
groups 1 and 2) (n=4/group). HRS/J hairless mice in normal control group did
not receive any UV-B radiation treatment. Inflammation was induced in mice
from pathological control group and two experimental groups as described in
the section of “2. Induction of inflammation and photodamage” under
“General Methods”.
Starting from the initiation of UV-B radiation, HRS/J mice in experimental
group 1 was administered orally with Solanum incanum L. solution, in which
the solution was prepared as described in the section of “1. Preparations of
water-soluble extract from Solanum incanum L. and Solanum incanum L.
solution containing the water-soluble extract” under “Experimental Materials”.
These mice were administered with Solanum incanum L. solution once a day
(1500 mg/kg), 7 times a week, during a 14-week period, and was
continuously observed for 60 wks (i.e., 60 wk experimental period). In
experimental group 2, the Solanum incanum L. gel prepared according to the
section of “2. Preparation of Solanum incanum L. gel containing the
water-soluble extract” under “Experimental Materials” was applied to dorsal
skin of the mice subjected to UV-B radiation. The gel was applied once a day
(dosage: 10-20 mg of gel per cm ), 5 times a week, during a 14-wk period,
and was observed for 60 wks. HRS/J hairless mice in normal control and
pathological control group were not treated with the Solanum incanum L.
solution or the Solanum incanum L. gel.
At the end of 26, 35, 38, 41, 52, 56, and 60 wks during the 60 wk
experimental period, the dorsal skin from HRS/J hairless mice in pathological
control and experimental groups 1 and 2 were subjected to analyses in Item A
(see below). In addition, after the 60 wk experimental period, the dorsal skin
obtained from HRS/J hairless mice in normal control, pathological control and
experimental group 2 were subjected to analyses in Item B as described
below. The dorsal skin tissues of the mice from pathological control and
experimental group 2 were obtained using surgical scissors and were
subjected to analyses in Item C as described below.
A. Analysis of skin tumor formation
Tumor number on the dorsal skin of HRS/J hairless mice from pathological
control and experimental groups 1 and 2 were observed by naked eyes.
Tumor size was recorded using digital caliper (Mitutoyo, NTD15P-6”CX).
Data for tumor number and volume are shown as mean ±SEM (p<0.05 is
statistically significant).
B. Evaluation of skin elasticity
Skin elasticity was evaluated by referencing pinch testing that is
mentioned in K. Tsukahara et al (2005), Biolo. Pharm. Bull., 28
(12):2302-2307. In brief, HRS/J hairless mice from normal control,
pathological control and experimental group 2 were placed on a platform. The
dorsal skin at the middle line of mouse body was pinched upward as much as
possible (without lifting the mouse) and then released. The recovery time for
the pinched skin to rebound to the original statue was measured.
C. Histochemical staining of elastic fiber
After the 60 wk experimental period, the skin tissues obtained from
HRS/J hairless mice in pathological control and experimental group 2 were
sectioned into 6μm thickness using the procedure set forth in the section of “3.
Tissue slice” under “General Methods”. Tissue sections were stained with
resorcin-fuchsin solution, Weigert’s iron hematoxylin and van Gieson’s
solution (all purchased from Muto Pure Chemicals Co., Ltd). Stained tissues
were observed under an optical microscope with a 100-400X magnification
and recorded with a digital camera (Olympus DP50, Japan).
A. Analysis of skin tumor formation
Tumor number over the course of the 60 wk experimental period is shown
in Figure 7. Tumor size measurement over the course of the 60 wk
experimental period is shown in Figure 8.
As shown in Figure 7 and 8, at 38 wk, the dorsal skin of the HSR/J
hairless mice from the pathological control group showed an acceleration of
tumor development. Conversely, a slower increase in tumor number and size
was observed in experimental groups 1 and 2 during the 60 wk experimental
period. These data suggest that Solanum incanum L. solution and Solanum
incanum L. gel can improve the photodamage caused by UV-B radiation and
alleviate skin pathologic change caused by photodamage.
B. Evaluation of skin elasticity
Pinch testing was done after the 60 wk experimental period on HRS/J
hairless mice from normal control, pathological control and experimental
group 2. As shown in Figure 9, pathological control group showed a
decreased elasticity compared to the normal control group since a longer
recovery time is required in the pathological control group; suggesting UV-B
exposure induces photodamage in HRS/J hairless mice. When Solanum
incanum L. gel was applied to dorsal skin of hairless mice in experimental
group 2, skin elasticity was greatly increased when compared to the
pathological control group. Data from these experiments suggest that
Solanum incanum L. gel can alleviate photodamage caused by UV-B and
improve skin elasticity.
C. Histochemical staining of elastic fiber
As shown in Figure 10, the occurrence of elastic fiber denaturation was
markedly increased in pathological control group. On the other hand, when
Solanum incanum L. gel was applied to the dorsal skin of hairless mice in
experimental group 2, there was less occurrence of elastic fiber denaturation
and the fibers remained long and intact. Data from these experiments
suggest that Solanum incanum L. gel of the present invention can alleviate
photodamage caused by UV-B exposure and improve solar elastosis.
In all, data from the above experiments support that the water-soluble
extract from Solanum incanum L. can prevent photodamage and improve
pathological changes on the skin caused by photodamage.
Example 4: Comparison of the effect of the Solanum incanum L. gel and
tretinoin on preventing UV-B-induced photodamage.
HRS/J hairless mice was randomly grouped into pathological control
group, tretinoin group and Solanum incanum L. gel group (n=5/group).
Induction of photodamage on HRS/J hairless mice from each group was
performed according to the section of “2. Induction of inflammation and
photodamage” under “General Methods”.
Starting from the initiation of UV-B radiation, HRS/J mice in tretinoin
group was applied with AIROL vanishing cream (contains 0.05% tretinoin, a
conventional active component for treating photodamage, topical dosage: 10
to 20 mg of AIROL vanishing cream per cm ). The cream was applied once a
day, 5 times a week, for 14 weeks, and was continuously observed for 35
weeks (i.e., 35 week experimental period). The dorsal skin of HRS/J hairless
mice in Solanum incanum L. gel group was applied with the Solanum
incanum L. gel obtained from the section of “2. Preparation of Solanum
incanum L. gel containing the water-soluble extract” under “Experimental
Materials”. The gel was applied once a day (dosage: 10-20 mg of gel /cm ), 5
times a week, during a 14-week period and was observed for 35 weeks.
HRS/J hairless mice in pathological control group were not treated with the
water-soluble extract.
Tumor number on the dorsal skin of the mice from tretinoin group and
Solanum incanum L. gel group was quantified at 0 week (i.e., before
exposure to UV-B radiation), and at the end of 2, 7, 12, 17, 22, 27, and 32
weeks during the 35 week experimental period based on the method
mentioned in Item A (Analysis of skin tumor formation) of Example 3. In
addition, HRS/J hairless mice from pathological control, tretinoin group, and
Solanum incanum L. gel group were subjected to analyses as mentioned in
Item B (Analysis of transepidermal water loss) of Example 2 and the following
Item A at 0 week and the end of 5, 10, 15, 20, 25, and 30 weeks during the 35
week experimental period.
A. Examination of water content in skin
Determination of water content in skin was examined by using an
evaporimeter (Tewameter TM 201R, Courage & Khazaka, Cologne,
Germany).
(1) Analysis of skin tumor formation
As shown in Fig. 11, at week 17, tretinoin group showed a dramatic
increase in average tumor number. Conversely, HRS/J hairless mice from
Solanum incanum L. gel group showed a slow increase in average tumor
number. These data suggest that Solanum incanum L. gel of the present
invention can more effectively improve photodamage caused by UV-B when
compared to tretinoin group, and alleviates pathological changes of the skin.
(2) Evaluation of transdermal water loss (TEWL)
As shown in Figure 12, during the 35 week experimental period, TEWL
rate was lower in Solanum incanum L. gel group when compared to
pathological and tretinoin groups. Specifically, at the end of 20, 25 and 30
weeks during the 35 week experimental period, there was a statistically
significant difference in TEWL between the pathological control group and
Solanum incanum L. gel group (p<0.05). These data suggest that Solanum
incanum L. gel of the present invention can effectively alleviate photodamage
induced by UV-B radiation and improve damage on stratum corneum caused
by photodamage.
(3) Evaluation of water content in skin
Water content in the dorsal skin of HRS/J hairless mice from each group
(pathological control, tretinion and Solanum incanum L. gel groups) was
determined at various time points throughout the 35 week experimental
period. As shown in Fig. 13, the mice treated with Solanum incanum L. gel
had a higher skin water content when compared to pathological control group
and tretinion group. Specifically, at the end of 25 weeks, the mice treated with
Solanum incanum L. gel showed a statistically significant water content as
compared to the pathological group or tretinoin group. These data suggest
that Solanum incanum L. gel of this invention is more effective in alleviating
photodamage caused by UV-B and improve skin water loss than tretinion
treatment.
In all, the water-soluble extract of this invention has been proven to
exhibit prevention of photodamage, improvement of pathological changes
caused by photodamage, and maintenance of moisture-retaining capacity
more effectively than what is often clinically used to treat and prevent
photodamage (such as tretinion).
All the patents and literature references cited in the present specification
as well as the references described therein, are hereby incorporated by
reference in their entirety. In case of conflict, the present description,
including definitions, will prevail.
While the present invention has been described in connection with what
are considered the most practical and preferred embodiments, it is
understood that this invention is not limited to the disclosed embodiments but
is intended to cover various arrangements included within the spirit and
scope of the broadest interpretation and equivalent arrangements.
Claims (24)
1. Use of a water-soluble extract from a plant of Solanum genus in the manufacture of a medicament for treating cutaneous photodamage, wherein said water-soluble extract comprises solamargine and 5 solasonine.
2. The use of claim 1, wherein said water-soluble extract comprises at least 60 wt% of solamargine and solasonine.
3. The use of claim 1, wherein said water-soluble extract comprises 60 wt%-90 wt% of solamargine and solasonine. 10
4. The use of any one of claims 1 to 3, wherein said cutaneous photodamage comprises one of the following symptoms: thinning of the skin, skin atrophy, decrease in collagen fiber and elastic fiber, elastosis, loss of skin elasticity, dryness, wrinkle formation, inflammatory cells infiltration, premature skin aging, vascular change, pigmentary change, 15 comedone, cyst and skin pathologic change.
5. The use of any one of claims 1 to 4, wherein the medicament when administered, is administered by an oral route.
6. The use of any one of claims 1 to 4, wherein the medicament is to be administered by an oral route. 20
7. The use of any one of claims 1 to 4, wherein the medicament is in a form for oral administration.
8. The use of any one of claims 1 to 4, wherein when administered, the medicament is administered by a topical route.
9. The use of any one of claims 1 to 4, wherein the medicament is 25 to be administered by a topical route.
10. The use of any one of claims 1 to 4, wherein the medicament is in a form for topical administration.
11. Use of a water-soluble extract from a plant of Solanum genus, wherein said water-soluble extract comprises solamargine and solasonine in the manufacture of a cosmetic composition.
12. The use of claim 11, wherein said water-soluble extract 5 comprises at least 60 wt% of solamargine and solasonine.
13. The use of claim 11, wherein said water-soluble extract comprises 60 wt%-90 wt% of solamargine and solasonine.
14. Use of any one of claims 11 to 13, further comprising a cosmetically acceptable adjuvant selected from the group consisting of 10 solvent, gelling agents, activating agents, preservatives, antioxidants, screening agents, chelating agents, surfactants, coloring agents, thickening agents, fillers, fragrance and odor absorbent.
15. Use of a water-soluble extract from a plant of Solanum genus in the manufacture of a medicament for treating inflammation, wherein said 15 water-soluble extract comprises solamargine and solasonine.
16. The use of claim 15, wherein said water-soluble extract comprises at least 60 wt% of solamargine and solasonine.
17. The use of claim 15, wherein said water-soluble extract comprises 60 wt%-90 wt% of solamargine and solasonine. 20
18. The use of any one of claims 15 to 17, wherein when administered, the medicament is administered by an oral route.
19. The use of any one of claims 15 to 17, wherein the medicament is to be administered by an oral route.
20. The use of any one of claims 15 to 17, wherein the medicament 25 is in a form for oral administration.
21. The use of any one of claims 15 to 17, wherein when administered, the medicament is administered by a topical route.
22. The use of any one of claims 15 to 17, wherein the medicament is to be administered by a topical route.
23. The use of any one of claims 15 to 17, wherein the medicament is in a form for topical administration. 5
24. A use as claimed in any one of claims 1 to 23, substantially as herein described with reference to any example thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW100116659A TWI476012B (en) | 2011-05-12 | 2011-05-12 | Treatment and/or prevention of inflammation and cutaneous photodamage and photoprotection of the skin with a water soluble extract from plant of solanum genus |
TW100116659 | 2011-05-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ598234A NZ598234A (en) | 2013-10-25 |
NZ598234B true NZ598234B (en) | 2014-01-28 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI495488B (en) | Compositions and methods for stimulating magp-1 to improve the appearance of skin | |
US20070036742A1 (en) | Methods and compositions for modulating hair growth or regrowth | |
TW200412992A (en) | Compositions containing peptide copper complexes and phytochemical compounds, and methods related thereto | |
US8197865B2 (en) | Methods and compositions for modulating hair growth or regrowth | |
TW200826971A (en) | Compositions and methods of their use for improving the condition and appearance of skin | |
CA2766631C (en) | Treatment and/or prevention of inflammation and cutaneous photodamage and photoprotection of the skin with a water-soluble extract from plant of solanum genus | |
KR20180081602A (en) | Compositions containing natural extracts and uses thereof for skin and hair | |
US20080268080A1 (en) | Use of alisma orientale in cosmetics and compositions thereof | |
KR101798632B1 (en) | Cosmetic composition containing stellera chamaejasme extract or fraction thereof and use thereof | |
JP2015508815A (en) | CPT-1 modulator and use of star fruit extract as a composition thereof | |
JP6545856B2 (en) | Composition for treating wounds, comprising a venom extract or fraction thereof, and method of treating wounds in an individual | |
NZ598234B (en) | Treatment and/or prevention of inflammation and cutaneous photodamage and photoprotection of the skin with a water-soluble extract from plant of solanum genus | |
KR20130092258A (en) | Cosmetic compositions having sebosuppressive effect | |
CN102872260A (en) | Method for treating and/or preventing inflammation and cutaneous photodamage by using water soluble extract from plant of Solanum genus and having photoprotective effect | |
KR101146133B1 (en) | Antiaging cosmetic composition containing extract of machilus thunbergii |